Skip to content
Clinical Trials – home
Not yet recruiting

Phase II study of sertraline plus standard chemotherapy drug combination in patients with advanced unresectable epithelioid pleural mesothelioma

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

Patients with Epithelioid pleural mesothelioma are being treated with a combination that includes the chemotherapy drugs cisplatin or carboplatin together with pemetrexed and the antidepressant medication sertraline. The purpose of the study is to compare how long patients stay free from disease worsening, known as progression‑free survival, with results that were seen in earlier research.

During the trial, the chemotherapy agents are given by intravenous infusion, which means the medicine is delivered directly into a vein, while sertraline is taken as a tablet by mouth. Treatment is given in repeated cycles over several months, with regular doctor visits and imaging scans to check the size of the tumor. After the treatment period, patients continue to be monitored for any changes in their health or disease status.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Baseline Assessments

    After you join the study, you will undergo a series of baseline examinations that may include physical checks, blood tests, and imaging scans to document the extent of your disease.

    These assessments create a reference point for later comparison of treatment effects.

  2. Step 2

    Start of Sertraline Therapy

    You will begin taking sertraline tablets, each containing 50 mg of sertraline hydrochloride, taken by mouth.

    The tablet is taken once each day for the duration of the study unless instructed otherwise.

  3. Step 3

    First Chemotherapy Cycle

    On the day of the first chemotherapy cycle you will receive an intravenous (IV) infusion of either cisplatin at a dose of 75 mg per square meter of body‑surface area (mg/m², a way to adjust the dose to your size), or carboplatin at a dose of 5 (unit defined by the study).

    Immediately after, you will receive an IV infusion of pemetrexed at a dose of 500 mg per square meter of body‑surface area (mg/m²).

    All infusions are administered through a vein and are performed under medical supervision.

  4. Step 4

    Repeated Chemotherapy Cycles

    The combination of the chosen platinum drug (cisplatin or carboplatin) with pemetrexed is repeated in subsequent cycles as defined by the study protocol.

    Each cycle includes the same IV infusions and is spaced according to the schedule set by the investigators.

  5. Step 5

    Ongoing Monitoring and Assessments

    Throughout the study you will have regular visits for safety checks, blood sampling, and imaging studies to evaluate disease status.

    You will also complete quality‑of‑life questionnaires that ask about symptoms and overall well‑being.

  6. Step 6

    Study Completion or Discontinuation

    The study ends for you when the planned treatment cycles are finished, if disease progression is observed, or if the investigator decides to stop treatment for safety reasons.

    At the end of the study a final assessment will be performed to collect all remaining data.

Who can join the trial?

9 criteria

  • You must sign a written informed consent before any study procedures, agreeing to follow the treatment and visits.
  • You must be at least 18 years old when you sign the consent.
  • You must have a new diagnosis of epithelioid malignant pleural mesothelioma (MPM) that has not been treated before, confirmed by a tissue test, preferably done during a minimally invasive chest surgery called video‑assisted thoracoscopic surgery (VATS).
  • Your cancer must be measurable, meaning at least one tumor can be seen on a CT scan in three different views so doctors can track its size over time using a special system called modified RECIST 1.1 for MPM. (If a tumor cannot be measured, the doctor may still consider you.)
  • Your disease must be surgically unresectable, meaning the tumor cannot be removed by surgery, and it must be at stage III‑IV according to the latest TNM cancer staging system.
  • You must have a sample of your tumor tissue available, either an older stored sample or a fresh biopsy taken within the last three months. The preferred type is a formalin‑fixed, paraffin‑embedded (FFPE) tissue block.
  • Your overall health must be good enough to have an ECOG performance status of 0 or 1, which means you are fully active or have only slight limitation in physical activity.
  • Your body’s major organs (like liver, kidneys, and bone marrow) must be working well enough as defined in the study’s lab tests.
  • You should be expected to live at least three more months, regardless of the cancer stage.

Who cannot join the trial?

15 criteria

  • Having a type of cancer called primitive peritoneal, pericardial or tunica vaginalis testis mesothelioma, which are mesotheliomas that arise in the abdomen lining, heart lining, or the covering of the testis.
  • Having had any epileptic seizures (sudden, uncontrolled electrical activity in the brain) in the past five years, or a history of status epilepticus (a prolonged seizure lasting more than five minutes or repeated seizures without recovery).
  • Having angle‑closure glaucoma with untreated narrow drainage angles in the eye, a condition that can sharply increase eye pressure and damage vision.
  • Having a known major bleeding disorder or coagulopathy (a problem with blood clotting), such as hemophilia or von Willebrand disease.
  • Having received an allogenic tissue or solid organ transplant (a transplant from another person).
  • Having a serious psychiatric disorder that is not under control or that requires ongoing medication.
  • Currently taking pimozide or any monoamine oxidase inhibitor (MAOI), or having taken an MAOI less than 14 days ago.
  • Having a known hypersensitivity reaction (allergic reaction) to any drug or substance used in this study.
  • Having uncontrolled heart problems, such as unstable ischemia (insufficient blood flow to the heart), uncontrolled irregular heartbeat (arrhythmia), severe heart failure (congestive heart failure), a prolonged heart‑beat interval (QTcF > 500 ms), or a birth‑related condition called long QT syndrome.
  • Having received radiation therapy (radiotherapy) within two weeks before starting the study, or having radiation‑related side effects that need steroid medication.
  • Having another cancer that is getting worse or that needed active treatment within the past three years, except for certain low‑risk skin cancers or early‑stage prostate cancer as described.
  • Having a serious active infection (grade 3 or higher), including active hepatitis B, hepatitis C, or HIV infection.
  • Not having fully recovered from major surgery or still having complications from surgery.
  • Having any other health condition, treatment, or lab abnormality that could interfere with the study results or make participation unsafe, as judged by the treating doctor.
  • Being pregnant, breastfeeding, or planning to become pregnant or father a child during the study period (from screening until 120 days after the last dose).
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Cisplatin

    is a chemotherapy drug that contains platinum. It is given through an IV infusion and works by damaging the DNA of cancer cells, which stops them from growing and dividing. In this trial, cisplatin is one of the chemotherapy options combined with the other drugs to treat advanced pleural mesothelioma.

  • Carboplatin

    is another platinum‑based chemotherapy medication. Like cisplatin, it is administered by IV infusion and interferes with the DNA of cancer cells, helping to slow or stop tumor growth. The study uses carboplatin as an alternative to cisplatin in the chemotherapy regimen.

  • Pemetrexed

    is a chemotherapy agent that blocks the production of DNA and RNA in cancer cells. Given by IV infusion, it helps prevent cancer cells from multiplying. In this trial, pemetrexed is combined with either cisplatin or carboplatin as part of the standard chemotherapy treatment for mesothelioma.

  • Sertraline

    is a medication usually used to treat depression and anxiety. In this study, it is being tested for a possible additional benefit against cancer when taken together with the chemotherapy drugs. Patients take sertraline by mouth in tablet form, and researchers are looking to see if it can improve the time patients live without the disease getting worse.

What is already known about the treatment

  • Cisplatin

    This drug is given as an intravenous infusion of a clear solution. It is a well‑established chemotherapy medicine that has been approved and studied for many years. It is mainly used to treat solid cancers such as lung, ovarian, testicular cancer and mesothelioma. It works by forming strong links in the DNA of cancer cells, which stops them from dividing, and it belongs to the class of platinum‑based antineoplastic agents.

  • Sertraline

    This medication comes as a film‑coated tablet taken by mouth. It is an approved antidepressant with a large amount of research supporting its safety and effectiveness. It is prescribed for depression, anxiety and related mood disorders, and is being tested as an additional treatment in cancer therapy. It increases the level of serotonin in the brain by blocking its re‑absorption, and it is classified as a selective serotonin reuptake inhibitor (SSRI).

  • Carboplatin

    The drug is administered through an intravenous infusion of a sterile solution. It is a widely used and approved chemotherapy agent that has been studied in many cancer trials. It is indicated for cancers such as ovarian, lung and mesothelioma. It damages cancer cell DNA by creating cross‑links, preventing the cells from multiplying, and it is part of the platinum‑based anticancer drug group.

  • Pemetrexed

    This medicine is delivered as an intravenous infusion of a solution for injection. It is an approved chemotherapy drug with extensive clinical data, especially for certain lung cancers and mesothelioma. It is used to treat malignant pleural mesothelioma and non‑small cell lung cancer. It blocks enzymes needed to make DNA and RNA, which stops cancer cells from growing, and it is classified as an antifolate antimetabolite.

Investigated diseases

Epithelioid pleural mesothelioma - Epithelioid pleural mesothelioma is a cancer that originates from the thin lining of the lungs called the pleura. It is characterized by cells that resemble normal epithelial cells. The tumor typically begins on the surface of the pleura and grows outward, thickening the lining and restricting lung expansion. Over time it can infiltrate nearby structures such as the chest wall, diaphragm, and ribs. It may also spread to the lining of the abdomen or to distant organs through the bloodstream or lymphatic system. The disease usually follows a pattern of gradual increase in tumor size and spread within the thoracic cavity.
Trial detailsLast updated 17 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-526791-23-00Protocol codeMESEEstimated enrolment83 patientsSponsorCentro Di Riferimento Oncologico Di Aviano

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.